CORE-IBD: a multidisciplinary international consensus initiative to develop a core outcome set for randomized controlled trials in inflammatory bowel disease

<p>Background & Aims</p> <p>End points to determine the efficacy and safety of medical therapies for Crohn’s disease (CD) and ulcerative colitis (UC) are evolving. Given the heterogeneity in current outcome measures, harmonizing end points in a core outcome set for randomized c...

Description complète

Détails bibliographiques
Auteurs principaux: Ma, C, Hanzel, J, Panaccione, R, Sandborn, WJ, D'Haens, GR, Ahuja, V, Atreya, R, Bernstein, CN, Bossuyt, P, Bressler, B, Bryant, RV, Cohen, B, Colombel, J-F, Danese, S, Dignass, A, Dubinsky, MC, Fleshner, PR, Gearry, RB, Hanauer, SB, Hart, A, Kotze, PG, Kucharzik, T, Lakatos, PL, Leong, RW, Magro, F, Panés, J, Peyrin-Biroulet, L, Ran, Z, Regueiro, M, Singh, S, Spinelli, A, Steinhart, AH, Travis, SP, van der Woude, CJ, Yacyshyn, B, Yamamoto, T, Allez, M, Bemelman, WA, Lightner, AL, Louis, E, Rubin, DT, Scherl, EJ, Siegel, CA, Silverberg, MS, Vermeire, S, Parker, CE, McFarlane, SC, Guizzetti, L, Smith, MI, Casteele, NV, Feagan, BG, Jairath, V
Autres auteurs: CORE-IBD Collaborators
Format: Journal article
Langue:English
Publié: Elsevier 2022